Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Health Canada Releases Guidelines for Psychedelic Therapy
Health Canada has released a Notice to Stakeholders, outlining its expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy.
This notice shows that the agency is acknowledging that psychedelic therapy will be a reality going forward, and is thus doing its bureaucratic duties and getting stuff down in writing as to expectations and standards of practice.
Good Results for COMP360 Psilocybin in Bipolar Disorder Study
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP. Some highlights.
- 12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder
- New data from COMPASS’ phase 2b trial, also presented at ACNP, validate potential of COMP360 psilocybin therapy in treatment-resistant depression
Enthea Announces Nationwide Rollout: Psychedelic Therapy as Workplace Benefit
The health insurance plan provider announced today its successful $2M seed round raise, led by Tabula Rasa Ventures, the first psychedelic accelerator for early-stage startups. The funds will be used to launch its services into 40 markets across the U.S. next year as well as grow Enthea’s customer base and provider network to further its mission of providing affordability and access to safe and effective psychedelic-assisted therapies for all who can benefit.
Irwin Naturals Emergence Completes Purchase of Florida Clinics
Irwin Naturals has completed the acquisition of the assets of Clare Clinic, Inc., d/b/a Florida Mind Health Center.
Klee Irwin, CEO of Irwin Naturals, said “Our roll-up is quickly gathering momentum. This is the eighth ketamine clinic we are adding to our growing portfolio in Florida and is part of our 17 clinics which we have either acquired or have a definitive agreement to acquire in the near future, in over ten states. Our mission is to make this amazingly effective treatment available and accessible throughout the country and beyond. We continue to add to our bottom line through these highly accretive transactions as we focus on acquiring profitable operations.”
Nova Mentis’ Psilocybin Preclinical Study Published in International Science Journal
Nova Mentis psilocybin preclinical study has been published in the Journal of Psychopharmacology, a fully peer-reviewed, international science journal. The Company’s preclinical research substantiates the therapeutic potential of microdosing by demonstrating that a repetitive low dose of psilocybin significantly modulated behavioural and cognitive defects in a genetic model of FXS.
On November 30, NOVA announced that it had submitted to Health Canada the first-ever Phase II A clinical trial application (CTA) testing the safety and efficacy of oral microdose psilocybin therapy for FXS.
